Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Uncertainties about the use of inhaled nitric oxide in preterm infants
Autore:
Mercier, JC;
Indirizzi:
Hop Robert Debre, Serv Pediat Reanimat, Div Neonatol & Paediat Intens Care, FR-75019 Paris, France Hop Robert Debre Paris France FR-75019 tens Care, FR-75019 Paris, France
Titolo Testata:
ACTA PAEDIATRICA
, volume: 90, anno: 2001, supplemento:, 436
pagine: 15 - 18
SICI:
0803-5253(200103)90:<15:UATUOI>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERSISTENT PULMONARY-HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY-FAILURE; NEWBORN LAMB; CIRCULATION; BIRTH; VASOCONSTRICTION; PATHOPHYSIOLOGY; MULTICENTER;
Keywords:
nitric oxide; persistent pulmonary hypertension;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Mercier, JC Hop Robert Debre, Serv Pediat Reanimat, Div Neonatol & PaediatIntens Care, 48 Blvd Serurier, FR-75019 Paris, France Hop Robert Debre 48 Blvd Serurier Paris France FR-75019 rance
Citazione:
J.C. Mercier, "Uncertainties about the use of inhaled nitric oxide in preterm infants", ACT PAEDIAT, 90, 2001, pp. 15-18

Abstract

Respiratory failure in the premature neonate is frequently complicated by pulmonary hypertension. When conventional therapies including administration of exogenous surfactant, conventional mechanical ventilation or high-frequency oscillatory ventilation using an appropriate high-volume strategy have failed. one should assess the pulmonary circulation status with colour-coded Doppler echocardiography. There is now considerable evidence that the regulation of foetal and postnatal pulmonary circulation occurs via nitric oxide (NO), and that persistent pulmonary hypertension of the neonate may berelated to a relative deficiency in NO release. Low-dose (10-20 ppm), short-duration (1-2 d) inhaled NO has generally been shown to improve the oxygenation and relieve pulmonary hypertension in premature neonates with severely hypoxaemic respiratory failure. Whether this therapy (eventually prolonged >1-3 wk?) would improve survival and lessen morbidity (e.g. intracranialhaemorrhage and chronic lung disease) remains to be proven by appropriately designed controlled trials. Until these issues can be clarified, NO therapy for premature neonates should be still considered as an experimental drug, and its use restricted to clinical studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 13:19:20